Funds will enable the completion of the ongoing Phase 2a clinical trial growing ectopic livers for patients with end stage liver disease and advance LyGenesis's pipeline of cell therapiesPITTSBURGH, Oct. 24, 2023 /PRNewswire/ -- LyGenesis, a clinical-stage biotechnology company developing cell therapies for patients with end stage liver disease, type 1 diabetes, end stage renal disease, and aging announced it has raised more than $19M in a Series A-2 financing round led by Prime Movers Lab, investors in breakthrough scientific startups, with follow-on funding from Juvenescence.

资金将有助于完成正在进行的2a期临床试验，为终末期肝病患者开发异位肝脏，并推进LyGenesis的细胞治疗管道匹兹堡，2023年10月24日/PRNewswire/-LyGenesis，一家临床阶段生物技术公司开发细胞治疗终末期肝病，1型糖尿病，终末期肾病，老龄化宣布，在由突破性科学创业公司投资者Prime Movers Lab领导的a-2系列融资中，其筹集了超过1900万美元，随后获得了Juvenescence的资助。

This funding round will enable LyGenesis to complete its Phase 2a clinical trial (ClinicalTrials.gov Identifier: NCT04496479) and advance its pipeline of cell therapies..

该资助轮将使LyGenesis能够完成其2a期临床试验（ClinicalTrials.gov标识符：NCT04496479）并推进其细胞治疗流程。。

Continue Reading

继续阅读

Lygenesis hepatocytes are engrafted into the lymph node where they can proliferate and form a functioning ectopic liver inside the body.

Lygenesis肝细胞被植入淋巴结，在那里它们可以增殖并在体内形成功能性异位肝脏。

'LyGenesis's regenerative cell therapies have the potential to transform the lives of patients who are either medically ineligible for an organ transplant or are awaiting an organ to become available. Using lymph nodes as bioreactors to grow ectopic organs is the type of platform technology that could revolutionize the treatment of multiple diseases and beneficially affect millions of lives,' said Justin Briggs, Biologist and Partner at Prime Movers Lab, who will be joining LyGenesis's Board of Directors..

'LyGenesis的再生细胞疗法有可能改变那些在医学上不适合器官移植或正在等待器官可用的患者的生活。Prime Movers实验室的生物学家兼合作伙伴Justin Briggs说，使用淋巴结作为生物反应器来生长异位器官是一种平台技术，可以彻底改变多种疾病的治疗方法，并有益地影响数百万人的生活。董事会。。

'We're delighted to continue our support for LyGenesis on its mission to restore the function of failing vital organs. By combining allogeneic cells from donated but discarded organs with a cost effective manufacturing process and engrafting their cell therapies using a low risk outpatient endoscopic ultrasound procedure, LyGenesis represents a truly remarkable opportunity,' said Richard Marshall, Chief Executive Officer of Juvenescence.

“我们很高兴继续支持LyGenesis恢复重要器官功能的使命。Juvenescence首席执行官理查德·马歇尔（Richard Marshall）说，通过将捐赠但丢弃的器官中的同种异体细胞与具有成本效益的制造工艺相结合，并使用低风险门诊内窥镜超声程序移植细胞疗法，淋巴结形成是一个真正非凡的机会。

The Series A-2 financing was also supported by Juvenescence and other investors..

A-2系列融资也得到了青少年和其他投资者的支持。。

ABOUT LYG-LIV-001 CELL THERAPYLYG-LIV-001 is LyGenesis's allogeneic cell therapy regulated by the FDA as a Section 351 Human Cellular Therapy/Product (HCT/P). This biologic therapy is created starting from donated livers, which are processed under Current Good Manufacturing Practice through a multi-step procedure to carefully isolate and suspend the hepatocytes in a solution to ready them for engraftment into that patient's mesenteric lymph nodes using an endoscopic ultrasound.

关于LYG-LIV-001细胞疗法YG-LIV-001是由FDA作为第351节人类细胞疗法/产品（HCT/P）监管的LyGenesis的同种异体细胞疗法。这种生物疗法是从捐赠的肝脏开始创建的，这些肝脏在目前的良好生产规范下通过多步骤程序进行处理，以小心地分离和悬浮肝细胞在溶液中，以便使用内窥镜超声将它们植入患者的肠系膜淋巴结中。

The lymph node then acts an as in vivo bioreactor, helping the hepatocytes to engraft, proliferate, and generate functional ectopic liver tissue. Unlike CRISPR or CAR-T therapies, LyGenesis's LYG-LIV-001 does not genetically engineer its cellular therapy, reducing the time and costs associated with manufacturing and commercializing the product.ABOUT LYGENESIS INC.LyGenesis is a clinical-stage biotechnology company whose cell therapies use patients' lymph nodes as bioreactors to regrow functioning ectopic organs.

然后淋巴结充当体内生物反应器，帮助肝细胞植入，增殖并产生功能性异位肝组织。与CRISPR或CAR-T疗法不同，LyGenesis的LYG-LIV-001不会对其细胞疗法进行基因工程改造，从而减少了与产品制造和商业化相关的时间和成本。关于LYGENESIS INC.LYGENESIS是一家临床阶段的生物技术公司，其细胞疗法使用患者的淋巴结作为生物反应器来再生功能性异位器官。

LyGenesis's lead allogeneic cell therapy program is currently in a Phase 2a clinical trial for patients with end stage liver disease (ClinicalTrials.gov Identifier: NCT04496479). LyGenesis's drug development pipeline includes cell therapies that can produce an ectopic thymus (for aging and multiple other potential indications), pancreas (for Type 1 diabetes), and kidney (for end stage renal disease).

LyGenesis的主要同种异体细胞治疗计划目前正处于终末期肝病患者的2a期临床试验中（ClinicalTrials.gov标识符：NCT04496479）。LyGenesis的药物开发流程包括可产生异位胸腺（用于衰老和多种其他潜在适应症），胰腺（用于1型糖尿病）和肾脏（用于终末期肾病）的细胞疗法。

Privately held with investment support from Prime Movers Lab and Juvenescence, and other investors, LyGenesis is headquartered in Pittsburgh, Pennsylvania. To learn more, please visit lygenesis.com.ABOUT PRIME MOVERS LABPrime Movers Lab invests in breakthrough scientific startups founded by Prime Movers, the inventors who transform billions of lives.

LyGenesis私人拥有Prime Movers Lab和Juvenescence以及其他投资者的投资支持，总部设在宾夕法尼亚州匹兹堡。要了解更多信息，请访问lygenesis.com.ABOUT PRIME MOVERS LABPrime MOVERS Lab投资于由PRIME MOVERS创立的突破性科学创业公司，PRIME MOVERS是改变数十亿人生活的发明者。

We invest in companies reinventing energy,.

我们投资于重塑能源的公司，。

Contact Information

联系信息

Media contact:

媒体联系：

Jacqueline Jeha, MPH

雅奎琳·杰哈，公共卫生硕士

+1.401.374.0955

+1.401.374.0955

[email protected]

[电子邮件保护]

SOURCE LyGenesis, Inc.

来源：LyGenesis，股份有限公司。